Danaher Corporation (NYSE:DHR) and Abcam (NASDAQ:ABCM) announced a definitive agreement for acquisition. In this deal, Danaher will acquire all currently outstanding shares of Abcam at a cash price of $24.00 per share. The total value of the acquisition stands at approximately $5.7 billion, accounting for assumed debts and subtracting acquired cash.
Upon completion, Abcam is expected to maintain its independent operational status and retain its unique brand identity within Danaher’s Life Sciences segment.
The transaction is set to close in mid-2024. Danaher intends to finance the acquisition through available cash and proceeds from the issuance of commercial paper.